BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet 2017;56:825-92. [PMID: 28210973 DOI: 10.1007/s40262-017-0506-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Jones NS, Winter H, Katsumoto TR, Florero M, Murray E, Walker H, Singh N, Chinn LW. Absence of Pharmacokinetic Interactions between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate. J Pharmacol Exp Ther 2019;371:202-7. [PMID: 31371481 DOI: 10.1124/jpet.119.257089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Saito A, Ishiguro N, Takatani M, Bister B, Kusuhara H. Impact of Direction of Transport on the Evaluation of Inhibition Potencies of Multidrug and Toxin Extrusion Protein 1 Inhibitors. Drug Metab Dispos 2021;49:152-8. [PMID: 33262224 DOI: 10.1124/dmd.120.000136] [Reference Citation Analysis]
3 Bolleddula J, Ke A, Yang H, Prakash C. PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. CPT Pharmacometrics Syst Pharmacol 2021;10:577-88. [PMID: 33822485 DOI: 10.1002/psp4.12619] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Huang C, Xia F, Xue L, Liu L, Bian Y, Jin Z, Miao L. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3. Cancer Chemother Pharmacol 2020;85:433-41. [DOI: 10.1007/s00280-019-03972-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
5 Mar PL, Horbal P, Chung MK, Dukes JW, Ezekowitz M, Lakkireddy D, Lip GYH, Miletello M, Noseworthy PA, Reiffel JA, Tisdale JE, Olshansky B, Gopinathannair R; from the American Heart Association Electrocardiography and Arrhythmias Committee of the Council of Clinical Cardiology. Drug Interactions Affecting Antiarrhythmic Drug Use. Circ Arrhythm Electrophysiol 2022;15:e007955. [PMID: 35491871 DOI: 10.1161/CIRCEP.121.007955] [Reference Citation Analysis]
6 Xiao G, Rowbottom C, Boiselle C, Gan L. Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K. Pharm Res 2018;35. [DOI: 10.1007/s11095-018-2445-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
7 Zhu P, Ye Z, Guo D, Xiong Z, Huang S, Guo J, Zhang W, Polli JE, Zhou H, Li Q, Shu Y. Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2). Pharm Res 2018;35:243. [PMID: 30361780 DOI: 10.1007/s11095-018-2526-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
8 Huang S, Li L, Wang Z, Xiao T, Li X, Liu S, Zhang M, Lu H, Wen Y, Shang D. Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level. Drug Des Devel Ther 2021;15:3903-13. [PMID: 34548782 DOI: 10.2147/DDDT.S327506] [Reference Citation Analysis]
9 Wongwan T, Chatsudthipong V, Soodvilai S. Farnesoid X Receptor Activation Stimulates Organic Cations Transport in Human Renal Proximal Tubular Cells. Int J Mol Sci 2020;21:E6078. [PMID: 32846898 DOI: 10.3390/ijms21176078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Colavita JPM, Todaro JS, de Sousa M, May M, Gómez N, Yaneff A, Di Siervi N, Aguirre MV, Guijas C, Ferrini L, Davio C, Rodríguez JP. Multidrug resistance protein 4 (MRP4/ABCC4) is overexpressed in clear cell renal cell carcinoma (ccRCC) and is essential to regulate cell proliferation. Int J Biol Macromol 2020;161:836-47. [PMID: 32553977 DOI: 10.1016/j.ijbiomac.2020.06.106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
11 Glatard A, Guidi M, Delacrétaz A, Dubath C, Grosu C, Laaboub N, von Gunten A, Conus P, Csajka C, Eap CB. Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses. Clin Pharmacokinet 2020;59:371-82. [PMID: 31552612 DOI: 10.1007/s40262-019-00821-w] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Raj GM, Mathaiyan J, Wyawahare M, Priyadarshini R. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients. Drug Metab Pers Ther 2018;33:175-85. [PMID: 30433870 DOI: 10.1515/dmpt-2018-0030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
13 Yuan S, Tao F, Zhang X, Zhang Y, Sun X, Wu D. Role of Wnt/β-Catenin Signaling in the Chemoresistance Modulation of Colorectal Cancer. Biomed Res Int 2020;2020:9390878. [PMID: 32258160 DOI: 10.1155/2020/9390878] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
14 Dong Y, Gong L, Lu X, Ye M, Lin Y, Xie S, Zhang J, Zhou F, Tang L, Zou W, Liu M. Changes of Transporters and Drug-metabolizing Enzymes in Nephrotic Syndrome. Curr Drug Metab 2020;21:368-78. [PMID: 32394830 DOI: 10.2174/1389200221666200512113731] [Reference Citation Analysis]
15 Koepsell H. Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advanced in vitro testing. Expert Opin Drug Metab Toxicol 2021;17:635-53. [PMID: 33896325 DOI: 10.1080/17425255.2021.1915284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Rosa B. Equine Drug Transporters: A Mini-Review and Veterinary Perspective. Pharmaceutics 2020;12:E1064. [PMID: 33171593 DOI: 10.3390/pharmaceutics12111064] [Reference Citation Analysis]
17 Ali Y, Shams T, Wang K, Cheng Z, Li Y, Shu W, Bao X, Zhu L, Murray M, Zhou F. The involvement of human organic anion transporting polypeptides (OATPs) in drug-herb/food interactions. Chin Med 2020;15:71. [PMID: 32670395 DOI: 10.1186/s13020-020-00351-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Karasik A, Váradi A, Szeri F. In vitro transport of methotrexate by Drosophila Multidrug Resistance-associated Protein. PLoS One 2018;13:e0205657. [PMID: 30312334 DOI: 10.1371/journal.pone.0205657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Zazuli Z, Duin NJCB, Jansen K, Vijverberg SJH, Maitland-van der Zee AH, Masereeuw R. The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition. Int J Mol Sci 2020;21:E6627. [PMID: 32927790 DOI: 10.3390/ijms21186627] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Costa ACC, Yamamoto PA, Lauretti GR, Benzi JR, Zanelli CF, Barz V, Ciarimboli G, Moraes NV. Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. The Journal of Clinical Pharmacology 2020;60:1076-86. [DOI: 10.1002/jcph.1603] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Tang J, Shen H, Zhao X, Holenarsipur VK, Mariappan TT, Zhang Y, Panfen E, Zheng J, Humphreys WG, Lai Y. Endogenous Plasma Kynurenic Acid in Human: A Newly Discovered Biomarker for Drug-Drug Interactions Involving Organic Anion Transporter 1 and 3 Inhibition. Drug Metab Dispos 2021;49:1063-9. [PMID: 34599018 DOI: 10.1124/dmd.121.000486] [Reference Citation Analysis]
22 Zhang K, Li M, Huang H, Li L, Yang J, Feng L, Gou J, Jiang M, Peng L, Chen L, Li T, Yang P, Yang Y, Wang Y, Peng Q, Dai X, Zhang T. Dishevelled1-3 contribute to multidrug resistance in colorectal cancer via activating Wnt/β-catenin signaling. Oncotarget 2017;8:115803-16. [PMID: 29383202 DOI: 10.18632/oncotarget.23253] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
23 Lazareth H, Delanoy N, Cohen R, Boissier E, Ayari H, Combe P, Crespel C, Mercadier-Riaz E, Karras A, Courbebaisse M, Thervet E, Pallet N. Nephrotoxicity Associated With Niraparib. Am J Kidney Dis 2020;76:898-900. [PMID: 32679152 DOI: 10.1053/j.ajkd.2020.05.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
24 Malik PRV, Yeung CHT, Ismaeil S, Advani U, Djie S, Edginton AN. A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease. J Clin Pharmacol 2020;60 Suppl 1:S52-62. [PMID: 33205424 DOI: 10.1002/jcph.1713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Rahman MM, Junaid M, Hosen SMZ, Mostafa M, Liu L, Benkendorff K. Mollusc-Derived Brominated Indoles for the Selective Inhibition of Cyclooxygenase: A Computational Expedition. Molecules 2021;26:6538. [PMID: 34770946 DOI: 10.3390/molecules26216538] [Reference Citation Analysis]
26 Sánchez-González PD, López-Hernández FJ, Dueñas M, Prieto M, Sánchez-López E, Thomale J, Ruiz-Ortega M, López-Novoa JM, Morales AI. Differential effect of quercetin on cisplatin-induced toxicity in kidney and tumor tissues. Food Chem Toxicol 2017;107:226-36. [PMID: 28669851 DOI: 10.1016/j.fct.2017.06.047] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
27 Morival C, Westerlynck R, Bouzillé G, Cuggia M, Le Corre P. Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining. Eur J Clin Pharmacol 2018;74:525-34. [DOI: 10.1007/s00228-017-2400-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
28 Zhao J, Feng WG, Wei Z, Zhou J, Chen XY, Zhang ZL. Follow-Up of Adefovir Dipivoxil Induced Osteomalacia: Clinical Characteristics and Genetic Predictors. Front Pharmacol 2021;12:636352. [PMID: 33995038 DOI: 10.3389/fphar.2021.636352] [Reference Citation Analysis]
29 Lien YH, Tsai HM. Stomatitis and Bone Marrow Suppression Followed by Leukoerythroblastosis in a Patient on Long-Term Low Dose Methotrexate Therapy. Am J Med 2022:S0002-9343(22)00540-X. [PMID: 35882283 DOI: 10.1016/j.amjmed.2022.07.007] [Reference Citation Analysis]
30 Wong YC, Centanni M, de Lange ECM. Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human. J Clin Pharmacol 2019;59:731-47. [PMID: 30676661 DOI: 10.1002/jcph.1365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
31 Vormann MK, Vriend J, Lanz HL, Gijzen L, van den Heuvel A, Hutter S, Joore J, Trietsch SJ, Stuut C, Nieskens TTG, Peters JGP, Ramp D, Caj M, Russel FGM, Jacobsen B, Roth A, Lu S, Polli JW, Naidoo AA, Vulto P, Masereeuw R, Wilmer MJ, Suter-Dick L. Implementation of a Human Renal Proximal Tubule on a Chip for Nephrotoxicity and Drug Interaction Studies. J Pharm Sci 2021;110:1601-14. [PMID: 33545187 DOI: 10.1016/j.xphs.2021.01.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
32 Heidari R. The footprints of mitochondrial impairment and cellular energy crisis in the pathogenesis of xenobiotics-induced nephrotoxicity, serum electrolytes imbalance, and Fanconi's syndrome: A comprehensive review. Toxicology 2019;423:1-31. [PMID: 31095988 DOI: 10.1016/j.tox.2019.05.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
33 Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther 2021;35:853-64. [PMID: 33818688 DOI: 10.1007/s10557-021-07147-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Kell DB. The Transporter-Mediated Cellular Uptake and Efflux of Pharmaceutical Drugs and Biotechnology Products: How and Why Phospholipid Bilayer Transport Is Negligible in Real Biomembranes. Molecules 2021;26:5629. [PMID: 34577099 DOI: 10.3390/molecules26185629] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Drozdzik M, Drozdzik M, Oswald S. Membrane Carriers and Transporters in Kidney Physiology and Disease. Biomedicines 2021;9:426. [PMID: 33919957 DOI: 10.3390/biomedicines9040426] [Reference Citation Analysis]
36 Potmešil P, Szotkowská R. Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes. Ther Adv Chronic Dis 2020;11:2040622320964152. [PMID: 33240477 DOI: 10.1177/2040622320964152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Gessner A, König J, Fromm MF. Clinical Aspects of Transporter-Mediated Drug-Drug Interactions. Clin Pharmacol Ther 2019;105:1386-94. [PMID: 30648735 DOI: 10.1002/cpt.1360] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 13.3] [Reference Citation Analysis]
38 Zou W, Shi B, Zeng T, Zhang Y, Huang B, Ouyang B, Cai Z, Liu M. Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking. Front Pharmacol 2021;12:746208. [PMID: 34912216 DOI: 10.3389/fphar.2021.746208] [Reference Citation Analysis]
39 Elsawy H, Alzahrani AM, Alfwuaires M, Abdel-Moneim AM, Khalil M. Nephroprotective effect of naringin in methotrexate induced renal toxicity in male rats. Biomed Pharmacother 2021;143:112180. [PMID: 34536756 DOI: 10.1016/j.biopha.2021.112180] [Reference Citation Analysis]
40 Ali Y, Shams T, Cheng Z, Li Y, Chun CS, Shu W, Bao X, Zhu L, Murray M, Zhou F. Impaired Transport Activity of Human Organic Anion Transporters (OATs) and Organic Anion Transporting Polypeptides (OATPs) by Wnt Inhibitors. J Pharm Sci 2021;110:914-24. [PMID: 33049263 DOI: 10.1016/j.xphs.2020.10.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Zheng X, Zhang JV, Bai Y, Wang J, Jiang M, Zeng S, Wang L. Upregulation of OATP1A2 in human oesophageal squamous cell carcinoma cells via the HDAC6-GCN5/PCAF-H3K9Ac axis. Xenobiotica 2021;:1-10. [PMID: 34823432 DOI: 10.1080/00498254.2021.2001076] [Reference Citation Analysis]
42 Barin-Le Guellec C, Largeau B, Bon D, Marquet P, Hauet T. Ischemia/reperfusion-associated tubular cells injury in renal transplantation: Can metabolomics inform about mechanisms and help identify new therapeutic targets? Pharmacol Res 2018;129:34-43. [PMID: 29309901 DOI: 10.1016/j.phrs.2017.12.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
43 Nigam AK, Li JG, Lall K, Shi D, Bush KT, Bhatnagar V, Abagyan R, Nigam SK. Unique metabolite preferences of the drug transporters OAT1 and OAT3 analyzed by machine learning. J Biol Chem 2020;295:1829-42. [PMID: 31896576 DOI: 10.1074/jbc.RA119.010729] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
44 Li Z, Fisher C, Gardner I, Ghosh A, Litchfield J, Maurer TS. Modeling Exposure to Understand and Predict Kidney Injury. Seminars in Nephrology 2019;39:176-89. [DOI: 10.1016/j.semnephrol.2018.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Khadka B, Lee JY, Park EK, Kim KT, Bae JS. Impacts of Drug Interactions on Pharmacokinetics and the Brain Transporters: A Recent Review of Natural Compound-Drug Interactions in Brain Disorders. Int J Mol Sci 2021;22:1809. [PMID: 33670407 DOI: 10.3390/ijms22041809] [Reference Citation Analysis]
46 Cusato J, Boglione L, De Nicolò A, Caviglia GP, Mornese Pinna S, Ciancio A, Troshina G, Smedile A, Antonucci M, Avataneo V, Palermiti A, Mula J, Manca A, Cariti G, Cantù M, Saracco GM, Di Perri G, D’avolio A. Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy. Pharmaceuticals 2022;15:355. [DOI: 10.3390/ph15030355] [Reference Citation Analysis]
47 Oude Munnink T, van der Meer A, de Haan J, Touw D, van Kruchten M. Reversible Impaired Methotrexate Clearance After Platinum-Based Chemotherapy for Osteosarcoma. Ther Drug Monit 2019;41:693-5. [PMID: 31169759 DOI: 10.1097/FTD.0000000000000662] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
48 Tan SPF, Scotcher D, Rostami-Hodjegan A, Galetin A. Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically-Based Pharmacokinetic Modeling and Dose Adjustment. Clin Pharmacol Ther 2022. [PMID: 35569107 DOI: 10.1002/cpt.2642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 de Klerk DJ, Honeywell RJ, Jansen G, Peters GJ. Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. Cancers (Basel). 2018;10. [PMID: 30544701 DOI: 10.3390/cancers10120503] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
50 Faucher Q, Alarcan H, Marquet P, Barin-Le Guellec C. Effects of Ischemia-Reperfusion on Tubular Cell Membrane Transporters and Consequences in Kidney Transplantation. J Clin Med 2020;9:E2610. [PMID: 32806541 DOI: 10.3390/jcm9082610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
51 Namasivayam V, Silbermann K, Pahnke J, Wiese M, Stefan SM. Scaffold fragmentation and substructure hopping reveal potential, robustness, and limits of computer-aided pattern analysis (C@PA). Comput Struct Biotechnol J 2021;19:3269-83. [PMID: 34141145 DOI: 10.1016/j.csbj.2021.05.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Nicklisch SCT, Hamdoun A. Disruption of small molecule transporter systems by Transporter-Interfering Chemicals (TICs). FEBS Lett 2020;594:4158-85. [PMID: 33222203 DOI: 10.1002/1873-3468.14005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Vriend J, Peters JGP, Nieskens TTG, Škovroňová R, Blaimschein N, Schmidts M, Roepman R, Schirris TJJ, Russel FGM, Masereeuw R, Wilmer MJ. Flow stimulates drug transport in a human kidney proximal tubule-on-a-chip independent of primary cilia. Biochim Biophys Acta Gen Subj 2020;1864:129433. [PMID: 31520681 DOI: 10.1016/j.bbagen.2019.129433] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
54 Lozano E, Briz O, Macias RIR, Serrano MA, Marin JJG, Herraez E. Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition. J Pers Med. 2018;8. [PMID: 29659532 DOI: 10.3390/jpm8020014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
55 Shen H, Scialis RJ, Lehman-mckeeman L. Xenobiotic Transporters in the Kidney: Function and Role in Toxicity. Seminars in Nephrology 2019;39:159-75. [DOI: 10.1016/j.semnephrol.2018.12.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
56 Nigam AK, Ojha AA, Li JG, Shi D, Bhatnagar V, Nigam KB, Abagyan R, Nigam SK. Molecular Properties of Drugs Handled by Kidney OATs and Liver OATPs Revealed by Chemoinformatics and Machine Learning: Implications for Kidney and Liver Disease. Pharmaceutics 2021;13:1720. [PMID: 34684013 DOI: 10.3390/pharmaceutics13101720] [Reference Citation Analysis]
57 Vriend J, Nieskens TTG, Vormann MK, van den Berge BT, van den Heuvel A, Russel FGM, Suter-Dick L, Lanz HL, Vulto P, Masereeuw R, Wilmer MJ. Screening of Drug-Transporter Interactions in a 3D Microfluidic Renal Proximal Tubule on a Chip. AAPS J 2018;20:87. [PMID: 30051196 DOI: 10.1208/s12248-018-0247-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
58 Morival C, Oumari S, Lenglet A, Le Corre P. Clinical pharmacokinetics of oral drugs in the treatment of multiple myeloma. Hematol Oncol 2017. [PMID: 29193184 DOI: 10.1002/hon.2485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
59 Sendra L, Olivera GG, López-andújar R, Serrano C, Rojas LE, Montalvá EM, Herrero MJ, Aliño SF. Pharmacogene Variants Associated with Liver Transplant in a Twelve-Year Clinical Follow-Up. Pharmaceutics 2022;14:354. [DOI: 10.3390/pharmaceutics14020354] [Reference Citation Analysis]
60 Smeets NJL, Litjens CHC, van den Heuvel JJMW, van Hove H, van den Broek P, Russel FGM, Koenderink JB, de Wildt SN. Completing the Enalaprilat Excretion Pathway-Renal Handling by the Proximal Tubule. Pharmaceutics 2020;12:E935. [PMID: 33007874 DOI: 10.3390/pharmaceutics12100935] [Reference Citation Analysis]
61 Wright SH. Molecular and cellular physiology of organic cation transporter 2. Am J Physiol Renal Physiol 2019;317:F1669-79. [PMID: 31682169 DOI: 10.1152/ajprenal.00422.2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
62 Smith JA, Le T, Martin GA, Gaikwad A, Sun CH, Nugent EK, Lucci JA 3rd. Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia. Gynecol Oncol 2019;152:265-9. [PMID: 30466807 DOI: 10.1016/j.ygyno.2018.11.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Gao J, Hou D, Hu P, Mao G. Curcumol increases the sensitivity of colon cancer to 5-FU by regulating Wnt/β-catenin signaling. Transl Cancer Res 2021;10:2437-50. [PMID: 35116559 DOI: 10.21037/tcr-21-689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Rayner SG, Phong KT, Xue J, Lih D, Shankland SJ, Kelly EJ, Himmelfarb J, Zheng Y. Reconstructing the Human Renal Vascular-Tubular Unit In Vitro. Adv Healthc Mater 2018;7:e1801120. [PMID: 30379416 DOI: 10.1002/adhm.201801120] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
65 Sánchez Rodríguez LH, Medina Pérez OM, Rondón González F, Rincón Cruz G, Rocha Muñoz L, Flórez-Vargas O. Genetic Polymorphisms in Multispecific Transporters Mitigate Mercury Nephrotoxicity in an Artisanal and Small-Scale Gold Mining Community in Colombia. Toxicol Sci 2020;178:338-46. [PMID: 32946573 DOI: 10.1093/toxsci/kfaa142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Saib S, Hodin S, He Z, Delézay O, Delavenne X. Is the human model RPTEC/TERT1 a relevant model for assessing renal drug efflux? Fundam Clin Pharmacol 2021;35:732-43. [PMID: 33185296 DOI: 10.1111/fcp.12631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Uwai Y. Enantioselective Drug Recognition by Drug Transporters. Molecules 2018;23:E3062. [PMID: 30467304 DOI: 10.3390/molecules23123062] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
68 Lončar J, Smital T. Interaction of environmental contaminants with zebrafish (Danio rerio) multidrug and toxin extrusion protein 7 (Mate7/Slc47a7). Aquatic Toxicology 2018;205:193-203. [DOI: 10.1016/j.aquatox.2018.10.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
69 Yao X, Watkins NH, Brown-Harding H, Bierbach U. A membrane transporter determines the spectrum of activity of a potent platinum-acridine hybrid anticancer agent. Sci Rep 2020;10:15201. [PMID: 32939009 DOI: 10.1038/s41598-020-72099-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Li YS, Tseng WL, Lu CY. Sensitive detection of quinoline-derivatized sitagliptin in small volumes of human plasma by MALDI-TOF mass spectrometry. Talanta 2020;218:121143. [PMID: 32797900 DOI: 10.1016/j.talanta.2020.121143] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Kobayashi M, Mizutani A, Okamoto T, Muranaka Y, Nishi K, Nishii R, Shikano N, Nakanishi T, Tamai I, Kleinerman ES, Kawai K. Assessment of drug transporters involved in the urinary secretion of [99mTc]dimercaptosuccinic acid. Nucl Med Biol 2021;94-95:92-7. [PMID: 33609918 DOI: 10.1016/j.nucmedbio.2021.01.004] [Reference Citation Analysis]
72 Li W, Jiao Z, Liu Y, Yao J, Li G, Dong J. Role of organic anion transporter 3 in the renal excretion of biapenem and potential drug-drug interactions. Eur J Pharm Sci 2021;162:105814. [PMID: 33753216 DOI: 10.1016/j.ejps.2021.105814] [Reference Citation Analysis]
73 Zhou Y, Du B, Kan M, Chen S, Tang BH, Nie AQ, Ye PP, Shi HY, Hao GX, Guo XL, Han QJ, Zheng Y, Zhao W. Drug Elimination Alteration in Acute Lymphoblastic Leukemia Mediated by Renal Transporters and Glomerular Filtration. Pharm Res 2020;37:158. [PMID: 32743772 DOI: 10.1007/s11095-020-02896-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Dubinsky S, Malik P, Hajducek DM, Edginton A. Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling. Clin Pharmacokinet 2022. [PMID: 35508593 DOI: 10.1007/s40262-022-01121-6] [Reference Citation Analysis]
75 Liao XY, Deng QQ, Han L, Wu ZT, Peng ZL, Xie Y, Wang GJ, Aa JY, Pan GY. Leflunomide increased the renal exposure of acyclovir by inhibiting OAT1/3 and MRP2. Acta Pharmacol Sin 2020;41:129-37. [PMID: 31341258 DOI: 10.1038/s41401-019-0283-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
76 Karimian Pour N, McColl ER, Piquette-Miller M. Impact of Viral Inflammation on the Expression of Renal Drug Transporters in Pregnant Rats. Pharmaceutics 2019;11:E624. [PMID: 31766631 DOI: 10.3390/pharmaceutics11120624] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
77 Vriend J, Vormann MK, Lanz HL, Joore J, Trietsch SJ, Russel FG, Jacobsen B, Roth A, Lu S, Polli JW, Naidoo AA, Masereeuw R, Wilmer MJ, Suter-dick L. Nephroscreen: A robust and versatile renal tubule-on-a-chip platform for nephrotoxicity assessment. Current Opinion in Toxicology 2021;25:42-8. [DOI: 10.1016/j.cotox.2021.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
78 Karimian Pour N, Piquette-Miller M. Dysregulation of renal transporters in a rodent model of viral Infection. Int Immunopharmacol 2020;80:106135. [PMID: 31951958 DOI: 10.1016/j.intimp.2019.106135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Dhaese SAM, Hoste EA, De Waele JJ. Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the ‘Maximum Tolerable Dose’. Antibiotics 2022;11:889. [DOI: 10.3390/antibiotics11070889] [Reference Citation Analysis]
80 Shen H. A pharmaceutical industry perspective on transporter and CYP-mediated drug–drug interactions: kidney transporter biomarkers. Bioanalysis 2018;10:625-31. [DOI: 10.4155/bio-2017-0265] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
81 Shen H, Holenarsipur VK, Mariappan TT, Drexler DM, Cantone JL, Rajanna P, Singh Gautam S, Zhang Y, Gan J, Shipkova PA, Marathe P, Humphreys WG. Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects. J Pharmacol Exp Ther 2019;368:136-45. [PMID: 30361237 DOI: 10.1124/jpet.118.252643] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
82 Weiss M, Siegmund W. Unusual Distribution Kinetics of Gadoxetate in Healthy Human Subjects Genotyped for OATP1B1: Application of Population Analysis and a Minimal Physiological-Based Pharmacokinetic Model. J Clin Pharmacol 2021;61:506-14. [PMID: 33084108 DOI: 10.1002/jcph.1762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Schijvens AM, de Wildt SN, Schreuder MF. Pharmacokinetics in children with chronic kidney disease. Pediatr Nephrol 2020;35:1153-72. [PMID: 31375913 DOI: 10.1007/s00467-019-04304-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
84 Ni Y, Duan Z, Zhou D, Liu S, Wan H, Gui C, Zhang H. Identification of Structural Features for the Inhibition of OAT3-Mediated Uptake of Enalaprilat by Selected Drugs and Flavonoids. Front Pharmacol 2020;11:802. [PMID: 32547398 DOI: 10.3389/fphar.2020.00802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
85 Vo D, Nguyen T, Maeng H. Effects of 1α,25-dihydroxyvitamin D3 on the pharmacokinetics and biodistribution of ergothioneine, an endogenous organic cation/carnitine transporter 1 substrate, in rats. J Pharm Investig . [DOI: 10.1007/s40005-022-00563-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Wang JQ, Yang Y, Cai CY, Teng QX, Cui Q, Lin J, Assaraf YG, Chen ZS. Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance. Drug Resist Updat 2021;54:100743. [PMID: 33513557 DOI: 10.1016/j.drup.2021.100743] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
87 Posma RA, Venema LH, Huijink TM, Westerkamp AC, Wessels AMA, De Vries NJ, Doesburg F, Roggeveld J, Ottens PJ, Touw DJ, Nijsten MW, Leuvenink HGD. Increasing metformin concentrations and its excretion in both rat and porcine ex vivo normothermic kidney perfusion model. BMJ Open Diabetes Res Care 2020;8:e000816. [PMID: 32816871 DOI: 10.1136/bmjdrc-2019-000816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
88 Frazier KS. The Impact of Functional and Structural Maturation of the Kidney on Susceptibility to Drug and Chemical Toxicity in Neonatal Rodents. Toxicol Pathol 2021;:1926233211035683. [PMID: 34338059 DOI: 10.1177/01926233211035683] [Reference Citation Analysis]
89 Bönisch H. Substrates and Inhibitors of Organic Cation Transporters (OCTs) and Plasma Membrane Monoamine Transporter (PMAT) and Therapeutic Implications. Handb Exp Pharmacol 2021;266:119-67. [PMID: 34495395 DOI: 10.1007/164_2021_516] [Reference Citation Analysis]
90 Yang X, Han L. Roles of Renal Drug Transporter in Drug Disposition and Renal Toxicity. Adv Exp Med Biol 2019;1141:341-60. [PMID: 31571169 DOI: 10.1007/978-981-13-7647-4_7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]